Levonorgestrel and ethinyl estradiol (LNG/EE) are two active ingredients used in combination in many modern birth control pills. This combination of hormones has been used in oral contraceptives for over 50 years and is one of the most commonly prescribed medications for women’s health. In this article, we will explore the benefits of LNG/EE for women’s health, including its contraceptive benefits, its potential to reduce the risk of certain cancers, and its ability to reduce the risk of developing certain medical conditions.
The primary benefit of LNG/EE is its contraceptive effect. It works by preventing ovulation, which means that the egg is not released from the ovary and therefore cannot be fertilized. This means that pregnancy is prevented. The contraceptive effect of LNG/EE is highly effective when taken as directed, with a failure rate of less than 1%. This makes it one of the most reliable methods of contraception available. In addition to its contraceptive benefits, LNG/EE can also help to regulate the menstrual cycle, making it more regular and reducing the risk of irregular bleeding.
In addition to its contraceptive benefits, LNG/EE has also been shown to reduce the risk of certain cancers. Studies have shown that LNG/EE can reduce the risk of ovarian cancer by up to 50%. It has also been shown to reduce the risk of endometrial cancer, which is cancer of the lining of the uterus, by up to 30%. This is an important benefit for women, as these types of cancer can be life-threatening.
In addition to its contraceptive and cancer risk reduction benefits, LNG/EE can also reduce the risk of developing certain medical conditions. Studies have shown that LNG/EE can reduce the risk of developing pelvic inflammatory disease, a serious infection of the reproductive organs, by up to 70%. It has also been shown to reduce the risk of developing benign breast disease, which can lead to breast cancer, by up to 50%. This is an important benefit for women, as these medical conditions can have serious implications for their health.
Levonorgestrel and ethinyl estradiol (LNG/EE) are two active ingredients used in combination in many modern birth control pills. This combination of hormones has been used in oral contraceptives for over 50 years and is one of the most commonly prescribed medications for women’s health. In this article, we have explored the benefits of LNG/EE for women’s health, including its contraceptive benefits, its potential to reduce the risk of certain cancers, and its ability to reduce the risk of developing certain medical conditions. Overall, LNG/EE is an effective and reliable form of contraception that can also provide additional benefits for women’s health.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation